Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
4 drugs for “PDAC - Pancreatic Ductal Adenocarcinoma”
Approved 1
- DaraxonrasibRevolution Medicines, Inc.PDAC - Pancreatic Ductal Adenocarcinoma
Phase 3 3
- AtebimetinibImmuneering CorpPDAC - Pancreatic Ductal Adenocarcinoma
- RMC-6236Revolution Medicines, Inc.PDAC - Pancreatic Ductal Adenocarcinoma
- ZoldonrasibRevolution Medicines, Inc.PDAC - Pancreatic Ductal Adenocarcinoma
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.